Adalimumab
What is Adalimumab?
Adalimumab, sold under the brand name Humira, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis (1) (3) (4). It is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFΞ±) (1) (2). Adalimumab was approved for medical use in the United States in 2002 and was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA) (1).
Dosage
The standard dose of Adalimumab is 40 mg administered by subcutaneous injection every other week for most indications (1) (5). However, the dosage may vary depending on the condition being treated and the patient's weight (1).
Side Effects
Common side effects of Adalimumab include injection site reactions, such as redness, pain, swelling, and itching (1) (3) (4). These side effects are usually mild and go away after a few days. Rarely, Adalimumab can cause serious side effects such as chest pain, heart palpitations, and difficulty breathing (1).
Interactions
Adalimumab can interact with other medications, including other immunosuppressive drugs, which can increase the risk of infection (5). Prior consultation with a medical expert is recommended before combining Adalimumab with other drugs or supplements.
Time of Day and With or Without Food
Adalimumab can be taken at any time of the day, with or without food (1).
Human Studies
Adalimumab has been extensively studied in humans and has been shown to be effective in treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis (1) (3) (4). It is generally well-tolerated, and its side effects are usually mild and go away after a few days (1).
In conclusion, Adalimumab is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It works by inactivating tumor necrosis factor-alpha (TNFΞ±). The standard dose is 40 mg administered by subcutaneous injection every other week for most indications. Adalimumab has been extensively studied in humans and has been shown to be effective in treating various conditions. Its side effects are usually mild and go away after a few days, and it can interact with other medications, including other immunosuppressive drugs.
Citations:
(1) https://en.wikipedia.org/wiki/Adalimumab
(2) https://www.ncbi.nlm.nih.gov/books/NBK557889/
(3) https://www.mayoclinic.org/drugs-supplements/adalimumab-subcutaneous-route/description/drg-20066817
(4) https://medlineplus.gov/druginfo/meds/a603010.html
(5) https://reference.medscape.com/drug/amjevita-humira-adalimumab-343187
(6) https://www.humira.com